How would you manage asymptomatic radiographic progression from M0 CRPC to M1 CRPC to bone?
PSA rose from 25 to 30 ng/mL over 6 months on darolutamide for M0 CRPC, prompting scans which showed oligometastatic disease to bone, not amenable to radiation.
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Duke University School of Medicine
Answered on
This is a relatively common scenario presently where the M0-->M1 transition is now occurring during potent AR inhibition in the nmCRPC setting. In general, I manage patients similarly to mCRPC patients progressing on an AR inhibitor and consider factors such as 1) pace of disease and symptoms, 2) co...
Join for free or sign in to see the full answer